Mies Kerstens
Sun 21 11:10
N1.3
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Challenges in the management of patients with Cushing’s syndrome and diabetes
Elizabeth Baranowski
Sun 21 12:39
OC1.3
Oral Communications 1 - Adrenal (Basic & Clinical)
Steroid Metabolomics for Accurate and Rapid Diagnosis of Inborn Steroidogenic Disorders
Qifu Li
Sun 21 13:03
OC1.5
Oral Communications 1 - Adrenal (Basic & Clinical)
Diagnostic accuracy of three confirmatory tests for primary aldosteronism: a prospective study and systematic review
Orit Barenholz-Goultschin
Sun 21 12:15
OC4.1
Oral Communications 4 - Thyroid Disease 1
Hypothyroidism in pregnancy is associated with twin pregnancies and with adverse obstetric outcome: Analysis of 142,277 deliveries data from a single center
Konrad Patyra
Sun 21 12:27
OC4.2
Oral Communications 4 - Thyroid Disease 1
Inducible thyrocyte-specific Gs alpha-deficient mice as a novel model for hypothyroidism
Sarantis Livadas
Sun 21 13:03
OC4.5
Oral Communications 4 - Thyroid Disease 1
Levothyroxine replacement therapy: once treatment is started, should it last indefinitely?
Jens Holst
Sun 21 15:30
S9.1
Symposium 9: Novel type 2 diabetes treatment: beyond glycaemic control
Experimental models
Wim Dik
Mon 22 10:30
S12.1
Symposium 12: New developments in Graves' orbitopathy
The orbital fibroblast: a key player and target for therapy in graves' orbitopathy
Eric Barros
Mon 22 12:15
OC5.1
Oral Communications 5 - Cardiovascular Endocrinology
Polarized epithelial cells release exosomes loaded with miRNAs capable of interacting with HSD11B2 and MR genes
Maxime Kwapich
Mon 22 12:39
OC5.3
Oral Communications 5 - Cardiovascular Endocrinology
Cardio Metabolic Assessment of Lamin A/C Mutation Carriers According To R482 or Non-R482 Mutation
Laurence Dumeige
Mon 22 13:03
OC5.5
Oral Communications 5 - Cardiovascular Endocrinology
Sex Dimorphism of Renal Corticosteroid Signaling during development and long term consequence on blood pressure.
Ron Piran
Mon 22 12:15
OC6.1
Oral Communications 6 - Diabetes Therapy and Complications
A passe-PAR2 for beta-cell regeneration and protection
Federica Ermetici
Mon 22 12:27
OC6.2
Oral Communications 6 - Diabetes Therapy and Complications
Insulin-Mimetic Effects of Short-Term Rapamycin in Type 1 Diabetic Patients prior Islet Transplantation
Marcin Chrusciel
Mon 22 12:15
OC7.1
Oral Communications 7 - Endocrine Tumours
Estrogens enhance gonadectomy-induced adrenocortical tumor progression in mice
Amit Tirosh
Mon 22 12:39
OC7.3
Oral Communications 7 - Endocrine Tumours
High Total 68Ga-DOTATATE-Avid Tumor Volume (TV) is Associated with Low Progression-Free Survival and High Disease-Specific Mortality Rate in Patients with Neuroendocrine Tumors
Eleonora Vitali
Mon 22 12:51
OC7.4
Oral Communications 7 - Endocrine Tumours
A novel insight into the anticancer mechanism of metformin in Pancreatic Neuroendocrine Tumor cells
Irina Agoulnik
Mon 22 13:03
OC7.5
Oral Communications 7 - Endocrine Tumours
Regulation of Steroid Receptor Signalling by Tumor Suppressor INPP4B
Ivan Bassi
Mon 22 12:27
OC8.2
Oral Communications 8 - Neuroendocrinology
Knocking down/out the prokineticin pathway during zebrafish development results in the GnRH neurons axons misguiding
Fernando Jimenez
Mon 22 13:03
OC8.5
Oral Communications 8 - Neuroendocrinology
Ephrin-B2 is required for pituitary development
Georgios Papadakis
Mon 22 16:00
N3.2
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Sexual hormones and bone, a close link throughout lifespan
Gherardo Mazziotti
Tue 23
MTE11
Meet the expert 11
Drug induced osteoporosis
Valeriano Leite
Tue 23 08:15
MTE14
Meet the expert 14
Thyroid carcinoma: complicated cases
Massimo Giusti
Tue 23 11:45
OC14.1
Oral Communications 14 - Thyroid Cancer
Anti-Mullerian hormone (AMH) in pre-menopausal females after ablative radioiodine (RAI) treatment for differentiated thyroid cancer (DTC): single-center study.
Shih-Ping Cheng
Tue 23 11:57
OC14.2
Oral Communications 14 - Thyroid Cancer
Suppression of heme oxygenase-1 inhibits growth and invasion of thyroid cancer
Brigitte Decallonne
Tue 23 12:21
OC14.4
Oral Communications 14 - Thyroid Cancer
Inverse relation between thyroid cancer incidence and threshold for thyroid surgery: a national population-based retrospective study
Ann McCormack
Tue 23 11:57
OC12.2
Oral Communications 12 - Pituitary Clinical
Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: Results from a European Society of Endocrinology (ESE) survey.
Guillem Cuatrecasas
Tue 23 12:09
OC12.3
Oral Communications 12 - Pituitary Clinical
Recombinant Growth Hormone added to physical therapy in GH-deficient adults with complete (ASIA A) Spine Injury (EudraCT 2011-005377-23)
Sabrina Chiloiro
Tue 23 12:33
OC12.5
Oral Communications 12 - Pituitary Clinical
Effects of Pegvisomant And Somatostatin Receptor Ligands On Risk Of Vertebral Fractures In Patients With Acromegaly
Sandrine Urwyler
Tue 23 12:09
OC11.3
Oral Communications 11 - Obesity
Interleukin-1 antagonism decreases cortisol levels in obese individuals
Natacha Germain
Tue 23 12:33
OC11.5
Oral Communications 11 - Obesity
Differentiating constitutional thinness from anorexia nervosa in DSM 5 era
Elisabeth Lerchbaum
Tue 23 15:30
S27.2
Symposium 27: Vitamin D beyond bone
Fertility
Daniel Ackermann
Tue 23 12:33
OC13.5
Oral Communications 13 - Reproduction & Endocrine Disruption
Urinary cadmium excretion is associated with increased synthesis of cortico- and sex steroids in a family-based Swiss population study
Simak Ali
London, UK
Mon 22 11:00
S11.2
Symposium 11: New Roles for Nuclear Receptors
Crosstalk between estrogen signalling and DNA damage repair
London, UK
Sundin Anders
Sun 21 11:00
S2.2
Symposium 2: Evolving diagnostics in adrenal and neuroendocrine tumours
Current status in morphological imaging in adrenal and gastrointestinal neuroendocrine tumours
Rosita Angela Condorelli
Tue 23 12:21
OC13.4
Oral Communications 13 - Reproduction & Endocrine Disruption
Diabetes mellitus: a new cause of male infertility
Tais Assmann
Sun 21 12:15
OC2.1
Oral Communications 2 - Diabetes Prediction and Complications
microRNA expression profile in plasma from patients with type 1 diabetes: a case-control study and bioinformatics analysis
Philippe Backeljauw
Cincinnati, USA
Sun 21 11:40
Guidelines session 1: Management of Turner Syndrome
The heart in Turner syndrome
Cincinnati, USA
Luigi Bartalena
Mon 22 11:00
S12.2
Symposium 12: New developments in Graves' orbitopathy
Management of Graves orbitopathy
Tomasz Bednarczuk
Mon 22 08:15
MTE7
Meet the expert 7
When and which treatment to use in Graves disease?
Christian Benedict
Tue 23 15:00
S28.1
Symposium 28: Sleep, love and reproduction
Candidate mechanisms underlying the association between poor sleep and obesity
Jerome Bertherat
France
Sun 21
ENDO-ERN session
Introduction and view from the ESE clinical committee
France
Johan Beun
't Harde, The Netherlands
Sun 21 12:45
N2.3
Nurses session: Nurses professional development and networking session
Introducing the E-learning module in Adrenal Insufficiency for endocrine nurses in The Netherlands
't Harde, The Netherlands
Felix Beuschlein
Zürich, Switzerland
Tue 23 16:00
S30.3
Symposium 30: Moving away from old-fashioned steroidogenesis: what are the clinical implications?
Glucocorticoid production in primary aldosteronism – from mechanisms to clinical implications
Zürich, Switzerland
Antonio Bianco
Chicago, USA
Sun 21 15:30
S6.1
Symposium 6: Treatment of hypothyroidism: what have we learned?
What is the clinical relevance of deiodinase polymorphisms?
Chicago, USA
Nadine Binart
Sun 21 10:30
S3.1
Symposium 3: From the pituitary to the periphery
Implication of the prolactin receptor in humans
Dennis Black
Mon 22
D3.2
Debate 3: Drug holiday in osteoporosis
Against
Sofie Bliddal
Tue 23 11:57
OC13.2
Oral Communications 13 - Reproduction & Endocrine Disruption
Thyroid peroxidase antibodies do not predict outcome in 900 women with recurrent pregnancy loss
Eva-Maria Bogner
Mon 22 12:15
OC8.1
Oral Communications 8 - Neuroendocrinology
Elucidating the molecular mechanisms underlying AIP dependent tumorigenesis.
Marek Bolanowski
Sun 21 16:30
S8.3
Symposium 8: Predictors of therapeutic response in functioning pituitary tumours
Clinical application and practice
Enzo Bonora
Tue 23 16:00
S29.3
Symposium 29: Novel predictors of diabetes
NAFLD, diabetes and CVD
Stefan Bornstein
Mon 22 16:00
S20.2
Symposium 20: Beta cell replacement and plasticity
New Strategies for beta cell replacement
Philippe Bouchard
Mon 22 08:15
MTE10
Meet the Expert 10
Contraception in women with obesity, metabolic syndrome and diabetes
Roger Bouillon
Tue 23 16:00
S27.3
Symposium 27: Vitamin D beyond bone
Muscles
Vickie Braithwaite
Cambridge, UK
Sun 21 11:00
S5.2
Symposium 5: EYES session
Vitamin D and rickets in African children
Cambridge, UK
Leticia Brondani
Sun 21 13:03
OC2.5
Oral Communications 2 - Diabetes Prediction and Complications
Urinary peptidomics for the detection of diabetic kidney disease
Michael Buchfelder
Erlangen, Germany
Mon 22 11:30
S13.3
Symposium 13: Challenging pituitary diseases
Sellar masses
Erlangen, Germany
Sarah Caixeta Cardoso
Sun 21 12:39
OC4.3
Oral Communications 4 - Thyroid Disease 1
A Novel Variant In The SERPINA7 Gene Causing Partial TBG Deficiency In A Woman And Two Male Siblings: Molecular and Protein Structural analysis
Cecilia Camacho-Hubner
Mon 22 12:51
OC8.4
Oral Communications 8 - Neuroendocrinology
Cerebrovascular stroke incidence in GH-Treated Adults: Experience from KIMS (Pfizer International Metabolic Database)
Luis Cardoso
Sun 21 11:50
Symposium 5: EYES session
Eyes activities and invitation to Eyes annual meeting
Bertrand Cariou
Mon 22 15:30
S16.1
Symposium 16: Late-breaking: the PCSK9 revolution
Beyond LDL lowering: the pleiotropic roles of PCSK9
Mon 22 16:30
S16.3
Symposium 16: Late-breaking: the PCSK9 revolution
PCSK9 inhibition in clinical practice: present and future
Enrico Carmina
Mon 22
D4.2
Debate 4: Is cardiovascular risk increased in women with PCOS?
Against
Justo Castaño
Sun 21 11:30
S3.3
Symposium 3: From the pituitary to the periphery
Somatostatin receptors: news in the pituitary, lessons for the periphery
Roland Chapurlat
Tue 23 11:00
S22.3
Symposium 22: Rare bone diseases
Fibrous dysplasia
Françoise Borson- Chazot
Mon 22 11:00
S14.2
Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
Rare acromegaly
Vasileios Chortis
Birmingham, United Kingdom
Tue 23 15:30
S30.2
Symposium 30: Moving away from old-fashioned steroidogenesis: what are the clinical implications?
Clinical relevance of steroid precursors in adrenocortical tumors
Birmingham, United Kingdom
Luisa Cianferotti
Tue 23 10:00
S22.1
Symposium 22: Rare bone diseases
Approach for clinicians
Frank Claessens
KU Leuven University, Leuven
Mon 22 11:30
S11.3
Symposium 11: New Roles for Nuclear Receptors
The role of androgens in bone
KU Leuven University, Leuven
Regis Cohen
Tue 23 11:57
OC11.2
Oral Communications 11 - Obesity
Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)
Patrick Collombat
Nice, France
Mon 22 16:30
S20.3
Symposium 20: Beta cell replacement and plasticity
Induction of pancreatic beta-like cell neogenesis
Nice, France
Ana Crujeiras
Tue 23 13:45
NSA6
New scientific approach 6
Mitochondrial epigenetics in obesity and its co-diseases
Patrizia D'amelio
Sun 21 15:30
S7.1
Symposium 7: Crosstalk between bone & other organ(ism)s
Immune system
Svetozar Damjanovic
Tue 23 10:00
S25.1
Symposium 25: HPA axis regulation during a woman's life: impact on metabolic outcomes
Molecular basis of the HPA axis regulation in woman during stress and pregnancy
Carla Dato
Mon 22 13:03
OC9.5
Oral Communications 9 - Thyroid Disease 2
Selenium Supplementation In The Management Of Thyroid Autoimmunity During Pregnancy: Results Of The ‘Serena Study' A Randomized, Double-Blind, Placebo-Controlled trial.
Hans DeVries
Amsterdam, The Netherlands
Mon 22 08:15
MTE6
Meet the expert 6
How best to utilise technology in diabetes?
Amsterdam, The Netherlands
Waljit Dhillo
London, UK
Tue 23 16:00
S28.3
Symposium 28: Sleep, love and reproduction
Kisspeptin & Neurokinin B
London, UK
Evanthia Diamanti-Kandarakis
Mon 22
EHM1
European Hormone Medal Lecture
Endocrine disruptors: Is it all Greek to us?
Andrew Dwyer
Lausanne, Switzerland
Sun 21 10:50
N1.2
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Links between hypogonadism, the metabolic syndrome and type 2 diabetes
Lausanne, Switzerland
Richard Eastell
Sheffield, UK
Sun 21
MTE5
Meet the expert 5
Modern spectrum of bone turnover markers - Are they clinically useful?
Sheffield, UK
Andreas Ebbehoj
Sun 21 12:51
OC1.4
Oral Communications 1 - Adrenal (Basic & Clinical)
The Epidemiology of Pheochromocytoma – Increasing Incidence and Changing Clinical Presentation. A population-based retrospective study 1977-2015.
Erik Eriksen
Sun 21 11:30
S1.3
Symposium 1: Clinical updates in Hypoparathyrodism
Therapeutic approaches
Javier Escalada
Sun 21 16:30
S9.3
Symposium 9: Novel type 2 diabetes treatment: beyond glycaemic control
SGLT2 inhibition: long term protective effects
Héctor Escobar-Morreale
Tue 23 08:15
MTE12
Meet the expert 12
A modern approach for treatment PCOS
Juan Falcon-Perez
Sun 21 14:15
NSA2
New Scientific Approach 2
Exosome profiling: potential in cancer diagnosis and stratification
Professor Sadaf Farooqi
Cambridge, UK
Sun 21 11:00
S4.2
Symposium 4: 2nd Joint Global Symposium on Obesity - the many dimensions of the childhood globesity problem
The Hunger Genes: Pathways to Obesity
Cambridge, UK
Patrick Fenichel
Tue 23 10:00
S21.1
Symposium 21: Environmental influences on endocrine systems
Lifestyle and environmental factors in metabolic diseases
Dr Frederic Flamant
Lyon, France
Mon 22 14:15
NSA4
New scientific approach 4
What is the CRISPR CAS9 technology?
Lyon, France
Dr Cecilia Follin
Lund, Sweden
Mon 22 08:15
MTNE1
Meet the nurse expert
Providing nursing care for the adult patient with endocrine late effects of cancer treatment
Lund, Sweden
Anna Formenti
Tue 23 10:30
S22.2
Symposium 22: Rare bone diseases
Osteogenesis imperfecta & Ehlers-Danlos Syndrome
Tue 23 12:09
OC10.3
Oral Communications 10 - Bone & Calcium Homeostasis
High prevalence of radiological vertebral fractures in patients with differentiated thyroid carcinoma undergoing L-thyroxine TSH-suppressive therapy
Gema Frühbeck
Tue 23 10:30
S24.2
Symposium 24: Obesity: Pharmacological solutions
The future drugs to come
Monica Gadelha
Sun 21 15:30
S8.1
Symposium 8: Predictors of therapeutic response in functioning pituitary tumours
Molecular profiling
Baptist Gallwitz
Sun 21 16:00
S9.2
Symposium 9: Novel type 2 diabetes treatment: beyond glycaemic control
Clinical studies on GLP1 - cardiovascular outcomes
Jean Gautier
Tue 23
MTE13
Meet the expert 13
What can new insulins provide for management of diabetes?
Iacopo Gesmundo
Tue 23 11:45
OC11.1
Oral Communications 11 - Obesity
Role of Extracellular Vesicles In The Crosstalk Between Adipocytes And Pancreatic Beta-Cells
Anne-Paule Gimenez-Roqueplo
Paris, France
Mon 22 16:00
S17.2
Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
Clinical implications of SDH mutations
Paris, France
Thomas Giordano
Ann Arbor, USA
Mon 22 15:30
S17.1
Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
Clinical consequences of the recent genomics findings in thyroid cancer
Ann Arbor, USA
Amod Godbole
Sun 21 12:51
OC4.4
Oral Communications 4 - Thyroid Disease 1
The TSH receptor reaches the trans-Golgi network to induce PKA activation and trigger gene transcription
Vincent Goffin
Tue 23 10:00
S23.1
Symposium 23: Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis
Prolactin regulation of prostate stem cells : potential implications in prostate cancer
Caroline Gorvin
Birmingham, UK
Tue 23 12:33
OC10.5
Oral Communications 10 - Bone & Calcium Homeostasis
Gα11-Phe220Ser loss-of-function mutation causes familial hypocalciuric hypercalcemia type-2 (FHH2) by disrupting a hydrophobic cluster critical for G-protein signaling
Birmingham, UK
Claus Gravholt
Sun 21 10:30
Guidelines session 1: Management of Turner Syndrome
Introduction
Yona Greenman
Tel Aviv, Israel
Sun 21
D1.1
Debate 1: Is there a role for medical therapy for non- functioning pituitary adenomas?
For
Tel Aviv, Israel
Stefan Groeneweg
Tue 23 16:00
S26.3
Symposium 26: Tissue specific defects in thyroid hormone action
Restoring TH action in patients with transporter defects: the Triac Trial
Martin Grussendorf
Tue 23 11:45
OC10.1
Oral Communications 10 - Bone & Calcium Homeostasis
Treatment of 711 patients with hypoparathyroidism: a retrospective study in 3 German Endocrine Centres.
Thomas Gudermann
Sun 21
MTBS1
Meet the basic scientist
Unravelling the role of transient receptor potential channels in endocrine regulation and metabolism
Susana Guerreiro
Tue 23 15:30
S28.2
Symposium 28: Sleep, love and reproduction
Oxytocin: from biology to love
Janne Hakkarainen
Tue 23 12:09
OC13.3
Oral Communications 13 - Reproduction & Endocrine Disruption
Sertoli Cell Expressed Hydroxysteroid (17BETA) Dehydrogenase 1 Is Required For Male Fertility
Fadil Hannan
Oxford, UK
Sun 21 11:00
S1.2
Symposium 1: Clinical updates in Hypoparathyrodism
Acquired hypoparathyroidism

Unknown speaker

Oxford, UK
Hans-Ulrich Häring
Mon 22
P4
Plenary 4
The role of brain insulin resistance for the development of prediabetic phenotypes
Dr Heike Heuer
Essen, Germany
Tue 23 15:00
S26.1
Symposium 26: Tissue specific defects in thyroid hormone action
Mouse models to study tissue specific hypothyroidism
Essen, Germany
Hans Hofland
Tue 23 15:00
S30.1
Symposium 30: Moving away from old-fashioned steroidogenesis: what are the clinical implications?
Clinical relevance of alternative synthesis of androgens
Anthony Hollenberg
Boston, USA
Sun 21 16:30
S6.3
Symposium 6: Treatment of hypothyroidism: what have we learned?
Rebuilding your own thyroid from stem cells; the future therapy of hypothyroidism?
Boston, USA
Alicja Hubalewska-Dydejczyk
Mon 22
MTE8
Meet the expert 8
How best to manage neuroendocrine tumours? - towards a new algorithm
Isabel Huguet
Tue 23 11:57
OC10.2
Oral Communications 10 - Bone & Calcium Homeostasis
Evaluation of bone quality, measured by trabecular bone score (TBS) in patients with primary hyperparathyroidism (PHH) with and without surgery
Simona Ioana Chisalita
Mon 22 12:51
OC6.4
Oral Communications 6 - Diabetes Therapy and Complications
Copeptin and its association to cardiovascular dysfunction in type 2 diabetes
Patricia Iozzo
Mon 22 08:15
MTBS2
Meet the basic scientist
Neuroimaging in obesity and diabetes: regulation and dysregulation of appetite and satiety
Franz Jakob
Mon 22 08:15
MTE9
Meet the expert 9
Sarcopenia- Why should we care?
Dr Sheba Jarvis
London, UK
Sun 21 12:27
OC3.2
Oral Communications 3 - Receptors & Signalling
Elucidating the role of Liver X receptors (LXRs) in the testis using lipid systems biology.
London, UK
Jens Jørgensen
Sun 21 08:15
MTE2
Meet the expert 2
Diagnosis and treatment of GH-deficiency: from transition to senescence
Anne Jouinot
Mon 22 12:27
OC7.2
Oral Communications 7 - Endocrine Tumours
Targeted molecular markers derived from genomic classification for Adrenocortical Cancer prognostication
Anders Juul
Copenhagen, Denmark
Sun 21
ENDO-ERN session
Opportunities, priorities, & dissemination of expertise
Copenhagen, Denmark
Kimberly Kamp
Mon 22 11:00
S14.3
Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
Rare hypoglycemia
Niki Karavitaki
Birmingham, UK
Mon 22 10:30
S13.1
Symposium 13: Challenging pituitary diseases
Hypophysitis
Birmingham, UK
Gerard Karsenty
Sun 21 16:00
S7.2
Symposium 7: Crosstalk between bone & other organ(ism)s
Regulation of adaptation to exercise by Osteocalcin
Electron Kebebew
Mon 22 16:00
S19.2
Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
When and how should we perform extensive surgery?
Fahrettin Kelestimur
Mon 22 16:00
S18.2
Symposium 18: Hyperandrogenism: challenges in clinical management
Metabolic perspectives for the non-classical CAH
Hector Keun
Sun 21 14:15
NSA1
New Scientific Approach 1
Identifying molecular signatures for cancer patient stratification via metabolomics and integrative bioinformatics
Noushafarin Khajavi
Sun 21 12:39
OC2.3
Oral Communications 2 - Diabetes Prediction and Complications
GLP-1 based multi-agonists-induced signaling includes profound TRP channel involvement in insulin secretion
Joan Khoo
Tue 23 12:21
OC11.4
Oral Communications 11 - Obesity
Comparing effects of weight loss by liraglutide with intensive lifestyle modification on hepatic steatosis, inflammation and stiffness, and insulin resistance in obese Asians with non-alcoholic fatty liver disease (NAFLD)
Reza Kiamanesh
Sun 21
D2.2
Debate 2: Incidentally discovered non-functioning pancreatic NENs: Surgery or not?
Against
Hye Kim
Mon 22 12:51
OC9.4
Oral Communications 9 - Thyroid Disease 2
Thyroid dysfunction during the use of PD-1/PD-L1 blockade predicts its therapeutic response in the patients with advanced non-small cell lung cancer
Janina Kirchner
Sun 21 12:30
N2.2
Nurses session: Nurses professional development and networking session
Utilising the Competence Framework to develop the role of Endocrine Nurses in Adrenal Insufficiency
Janis Klovins
Mon 22 12:39
OC6.3
Oral Communications 6 - Diabetes Therapy and Complications
Alterations in DNA methylation from peripheral blood cells in humans treated with metformin.
Ulrich Knigge
Sun 21
D2.1
Debate 2: Incidentally discovered non-functioning pancreatic NENs: Surgery or not?
For
Mikael Knip
Tue 23 15:00
S29.1
Symposium 29: Novel predictors of diabetes
Type 1 Diabetes
Nazarii Kobyliak
Sun 21 12:51
OC2.4
Oral Communications 2 - Diabetes Prediction and Complications
Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial
Tomaz Kocjan
Tue 23 12:21
OC10.4
Oral Communications 10 - Bone & Calcium Homeostasis
The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment
Josef Köhrle
Sun 21 11:40
S5.4
Symposium 5: EYES session
Endocrine Connections - the place to publish for the early career endocrinologist
John Kopchick
Ohio, USA
Sun 21 11:00
S3.2
Symposium 3: From the pituitary to the periphery
GHR : are there benefits of endocrine defects?
Ohio, USA
Dr Tim Korevaar
Netherlands, Netherlands
Sun 21 10:40
S5.1
Symposium 5: EYES session
Effects of maternal thyroid function on infant neurodevelopment
Netherlands, Netherlands
Jette Kristensen
Sun 21
ENDO-ERN session
The patient’s view
Matthias Kroiss
Sun 21 12:15
OC1.1
Oral Communications 1 - Adrenal (Basic & Clinical)
High resolution tissue mass spectrometry imaging – a new tool for identification of prognostic markers in adrenocortical carcinoma
Heiko Krude
Berlin, Germany
Sun 21
MTE4
Meet the expert 4
Optimised treatment for congenital hypothyroidism throughout lifetime
Berlin, Germany
Dr Peter Kühnen
Berlin, Germany
Tue 23 10:00
S24.1
Symposium 24: Obesity: Pharmacological solutions
MSH analogs
Berlin, Germany
André Lacroix
Sun 21 17:30
P3
Plenary 3
Update on regulation of steroidogenesis by aberrant hormone receptors
Professor Bente Langdahl
Aarhus, Denmark
Mon 22
D3.1
Debate 3: Drug holiday in osteoporosis
For
Aarhus, Denmark
Professor Mike Lean
Glasgow, United Kingdom
Tue 23 11:00
S24.3
Symposium 24: Obesity: Pharmacological solutions
Solutions update for medically complicated obesity
Glasgow, United Kingdom
Sophie Leboulleux
Geneva, Switzerland
Tue 23
D5.2
Debate 5: Should we still ablate all patients undergoing total thyroidectomy for thyroid cancer?
Against
Geneva, Switzerland
Julika Lietzow
Sun 21 12:51
OC3.4
Oral Communications 3 - Receptors & Signalling
Treatment with thyroid hormone metabolite 3,5-T2 alters cholesterol and sex steroid metabolism in mouse liver
Agnes Linglart
Paris, France
Sun 21 10:30
S1.1
Symposium 1: Clinical updates in Hypoparathyrodism
Congenital hypoparathyroidism
Paris, France
Dr Sofia Llahana
London, UK
Sun 21 12:55
N2.4
Nurses session: Nurses professional development and networking session
Developing a european position statement for endocrine nurses providing care for patients with adrenal insufficiency
London, UK
Tim Lobstein
Sun 21 11:30
S4.3
Symposium 4: 2nd Joint Global Symposium on Obesity - the many dimensions of the childhood globesity problem
Policy Response to Childhood Obesity
Miguel López
Sat 20
EJE1
European Journal of Endocrinology Prize Lecture
Hypothalamic AMPK: a golden target against obesity?
Anton Luger
Mon 22 12:15
European Union of Medical Specialists (UEMS), Section of Endocrinology
Introduction
Markus Luster
Tue 23
D5.1
Debate 5: Should we still ablate all patients undergoing total thyroidectomy for thyroid cancer?
For
Valery Lyssenko
Tue 23 15:30
S29.2
Symposium 29: Novel predictors of diabetes
Clinical and genetic indicators
Leocadio Mañas
Sun 21 08:15
MTE1
Meet the expert 1
How to manage diabetes in the elderly?
David Mangelsdorf
Sun 21 09:30
P2
Plenary 2
The secret life of FGF21
Camilla Maria Falch
Mon 22 12:39
OC8.3
Oral Communications 8 - Neuroendocrinology
RNA sequencing and RT-qPCR identify different gene expression profiles in fast- vs. slow-growing non-functioning pituitary adenomas
Laura Marinis
Mon 22 11:00
S13.2
Symposium 13: Challenging pituitary diseases
Empty sella
Luis Masana
Tue 23
MTE16
Meet the expert 16
New treatment approaches in dyslipidemia
George Mastorakos
Tue 23 10:30
S25.2
Symposium 25: HPA axis regulation during a woman's life: impact on metabolic outcomes
HPA axis, insulin resistance and adipocytokines in the fetal-maternal unit
Liubov Matchekhina
Sun 21 11:20
S5.3
Symposium 5: EYES session
Carbohydrate metabolism in patients with Cushing disease: a glance at the incretin system
Mickael Mathieu
Sun 21 12:27
OC1.2
Oral Communications 1 - Adrenal (Basic & Clinical)
EZH2 : a master regulator of adrenal cortex homeostasis and zonation
Dídac Mauricio
Tue 23
D6.2
Debate 6: Is it time for initial combination in type 2 diabetes?
Against
Claudia Maushart
Mon 22 12:27
OC9.2
Oral Communications 9 - Thyroid Disease 2
Effect of restoration of euthyroidism in patients with hypothyroidism on cold induced thermogenesis
Bruce McEwen
Tue 23 09:00
IPSEN1
IPSEN Fondation Lecture
Endocrine Regulations Prize lecture : Redefining neuroendocrinology: stress, sex and cognitive and emotional regulation
Shlomo Melmed
Los Angeles CA , USA
Tue 23 10:30
S23.2
Symposium 23: Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis
Does GH enable neoplastic growth?
Los Angeles CA , USA
Miguel Melo
Mon 22 16:30
S19.3
Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
Dynamic risk stratification in low-risk vs high-risk patients
Tue 23 12:09
OC14.3
Oral Communications 14 - Thyroid Cancer
TERT, BRAF and NRAS in the molecular profile of metastatic thyroid cancer: differences between primary and distant disease
Geltrude Mingore
Mon 22 10:30
S15.1
Symposium 15: Metabolic surgery: mechanisms to clinical results
The upper gut anti-incretin theory
José Miranda
Mon 22 16:00
S16.2
Symposium 16: Late-breaking: the PCSK9 revolution
New strategies for inhibiting PCSK9
Gilles Mithieux
Mon 22 11:00
S15.2
Symposium 15: Metabolic surgery: mechanisms to clinical results
The role of bile in metabolic surgery
Ahmad Moolla
Sun 21 13:03
OC3.5
Oral Communications 3 - Receptors & Signalling
Accurate staging of non-alcoholic fatty liver disease through analysis of the urinary steroid metabolome
Pauline Musson
Mon 22 15:30
N3.1
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Prevalance and treatment of vitamin D deficiency in children
Jan Nedergaard
Stockholm, Sweden
Mon 22 18:00
P5
Plenary 5
Browning of adipose tissue and metabolic regulation
Stockholm, Sweden
Susanne Neumann
Tue 23 14:05
NSA5.2
New scientific approach 5
Small molecule agonists and antagonists as potential new therapeutics targeting the TSH receptor
Michael O'Reilly
Dublin, Ireland
Sun 21 12:39
OC3.3
Oral Communications 3 - Receptors & Signalling
AKR1C3-mediated adipose androgen generation drives lipotoxicity in polycystic ovary syndrome
Dublin, Ireland
Salvatore Oliviero
Mon 22 14:15
NSA3
New scientific approach 3
Genomic approaches on epigenetics
Marsha Ooswaard
Mon 22 16:30
N3.3
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Prevention and management of post - menopausal osteoporosis
Renato Pasquali
Mon 22
CET1
Clinical Endocrinology Trust Lecture
New perspectives on the definition and management of the polycystic ovary syndrome
Ans van Pelt
Sun 21 16:00
S10.2
Symposium 10: The challenges of Male Fertility
Fertility preservation in pre-pubertal and young males
Alberto Pereira
Sun 21
ENDO-ERN session
Endo-ERN: introduction to a unique network
Professor Petros Perros
United Kingdom
Mon 22 11:30
S12.3
Symposium 12: New developments in Graves' orbitopathy
How to predict progression in Graves' orbitopathy
United Kingdom
Milan Petakov
Tue 23 08:15
MTE15
Meet the expert 15
Gaucher's disease: interdisciplinary management
Stephan Petersenn
Mon 22 10:30
S14.1
Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
Rare Cushing's
Patrick Petrossians
Sun 21 16:00
S8.2
Symposium 8: Predictors of therapeutic response in functioning pituitary tumours
Imaging
Marija Pfeifer
Mon 22 16:30
S18.3
Symposium 18: Hyperandrogenism: challenges in clinical management
Hyperandrogenism and cardiometabolic risk
Nelly Pitteloud
Lausanne, Switzerland
Sun 21 16:30
S10.3
Symposium 10: The challenges of Male Fertility
Pubertal induction and hormone replacement in young males
Lausanne, Switzerland
Michael Pollak
Tue 23 11:00
S23.3
Symposium 23: Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis
Is reducing insulin-resistance relevant to prevent cancer?
Vickas Prassad
Sun 21 11:30
S2.3
Symposium 2: Evolving diagnostics in adrenal and neuroendocrine tumours
Current status in functional imaging
Stefano Prato
Tue 23
D6.1
Debate 6: Is it time for initial combination in type 2 diabetes?
For
Michel Pugeat
Mon 22 15:30
S18.1
Symposium 18: Hyperandrogenism: challenges in clinical management
Hyperandrogenic states: pitfalls in diagnostic approach
Richard Quinton
London, UK
Mon 22 12:20
European Union of Medical Specialists (UEMS), Section of Endocrinology
Endocrine Training and Service around Europe
London, UK
Harpal Randeva
Mon 22
D4.1
Debate 4: Is cardiovascular risk increased in women with PCOS?
For
Hollie Raynor
Sun 21 10:30
S4.1
Symposium 4: 2nd Joint Global Symposium on Obesity - the many dimensions of the childhood globesity problem
Efficacy & Effectiveness of Physical Activity & Nutrition Interventions in Childhood Obesity Treatment
Jose Romero
Mon 22 13:03
OC6.5
Oral Communications 6 - Diabetes Therapy and Complications
Activation of the Renin-Angiotensin II-Aldosterone-System Leads to Increases in Extracellular Protein Disulfide Isomerase Activity: Role in Insulin Resistance
Theo Sas
Rotterdam, The Netherlands
Sun 21 10:40
Guidelines session 1: Management of Turner Syndrome
Growth and puberty induction
Rotterdam, The Netherlands
Patrick Scheerer
Tue 23 13:45
NSA5.1
New scientific approach 5
New strategies to crystallize endocrine disease related-GPCRs
Nadia Schoenmakers
Cambridge, United Kingdom
Tue 23 15:30
S26.2
Symposium 26: Tissue specific defects in thyroid hormone action
Syndromes of decreased sensitivity to TH
Cambridge, United Kingdom
Jean Scoazec
Mon 22 16:30
S17.3
Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
Will genomics help to finally classify NETs?
Elena Shelestova
Sun 21 10:30
N1.1
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Diagnosis and management of hypothyroidism in patients with diabetes mellitus
Alda Pereira Silva
Mon 22 12:51
OC5.4
Oral Communications 5 - Cardiovascular Endocrinology
Food History Characterization of Portuguese Centenarians, Nutritional Biomarkers And Cardiovascular Risk: Case Control Study
Manuel Simões
Tue 23
P6
Plenary 6
Thyroid oncology in the crossroads of precision and narrative medicine
Sofia Sjöberg
Sun 21 11:30
N1.4
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
At risk of two endocrine emergencies: the patient with Type 1 diabetes and Addison’s disease
Klara Sjögren
Sun 21 16:30
S7.3
Symposium 7: Crosstalk between bone & other organ(ism)s
Microbiome
Anna Skalniak
Mon 22 12:39
OC9.3
Oral Communications 9 - Thyroid Disease 2
How much of the genetic predisposition to Hashimoto’s thyroiditis can be explained by genes commonly associated with the disease?
Professor Lee Smith
New South Wales, Australia
Sun 21 15:30
S10.1
Symposium 10: The challenges of Male Fertility
Manipulating testicular androgen production to promote lifelong male health
New South Wales, Australia
Eyun Song
Tue 23 12:33
OC14.5
Oral Communications 14 - Thyroid Cancer
Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classical papillary carcinoma?
Valeria Sordi
Mon 22 15:30
S20.1
Symposium 20: Beta cell replacement and plasticity
Reprogramming and differentiation of skin fibroblasts into beta cells for the cure of diabetes
Markus Stoffel
Tue 23
MTBS3
Meet the basic scientist
MicroRNAs and the regulation of glucose and lipid metabolism
Yoshiyu Takeda
Sun 21 12:15
OC3.1
Oral Communications 3 - Receptors & Signalling
Epigenetic regulation of aldosterone synthase gene, CYP11B2 by potassium
Raj Thakker
Oxford, United Kingdom
Sun 21 10:30
S2.1
Symposium 2: Evolving diagnostics in adrenal and neuroendocrine tumours
Role of genetic and biomarker tests for diagnosis of neuroendocrine tumours (NETs)
Oxford, United Kingdom
Jeremy Tomlinson
Oxford, UK
Tue 23 11:00
S25.3
Symposium 25: HPA axis regulation during a woman's life: impact on metabolic outcomes
11β-hydroxysteroid dehydrogenase activity, androgen excess, and metabolic outcomes in woman
Oxford, UK
Jorma Toppari
Tue 23 10:30
S21.2
Symposium 21: Environmental influences on endocrine systems
Evidence on reproductive disorders through endocrine disruption in-utero
Stelios Tsagarakis
Sun 21
D1.2
Debate 1: Is there a role for medical therapy for non- functioning pituitary adenomas?
Against
Professor Matthias Tschöp
Munich, Germany
Sat 20
GH1
Geoffrey Harris Lecture
Toward hormone-based precision medicines for metabolic diseases
Munich, Germany
Tanya Urquhart
Sun 21 08:15
Meet the nurse expert
Endocrine late effects of cancer treatment in children: providing nursing care and seamless transition
Janielle Van der Velden
Sun 21 11:10
Guidelines session 1: Management of Turner Syndrome
Adult aspects
Josep Vidal
Mon 22 11:30
S15.3
Symposium 15: Metabolic surgery: mechanisms to clinical results
Long term effects of metabolic surgery
Dr Edward Visser
Rotterdam, The Netherlands
Mon 22 12:50
European Union of Medical Specialists (UEMS), Section of Endocrinology
Exchange in Endocrinology Expertise (3E) Programme
Rotterdam, The Netherlands
Paolo Vitti
Mon 22 15:30
S19.1
Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
Treatment and follow-up of microcarcinomas
Dr David Volle
Clermont-Ferrand, France
Mon 22 10:30
S11.1
Symposium 11: New Roles for Nuclear Receptors
Identification of nuclear receptors network in male fertility
Clermont-Ferrand, France
Henry Vὂlzke
Tue 23 11:00
S21.3
Symposium 21: Environmental influences on endocrine systems
EUthyroid: Towards a euthyroid Europe
Professor John Wass
Oxford, United Kingdom
Sat 20
P1
Plenary 1
The fantastical world of hormones
Oxford, United Kingdom
Wilmar Wiersinga
Amsterdam, The Netherlands
Sun 21 16:00
S6.2
Symposium 6: Treatment of hypothyroidism: what have we learned?
T4/T3 combination therapy: is there a true effect?
Amsterdam, The Netherlands
Catherine Williamson
London, UK
Sun 21
MTE3
Meet the expert 3
Hormone-secreting adrenal tumours in pregnancy
London, UK
Przemyslaw Witek
Tue 23 12:21
OC12.4
Oral Communications 12 - Pituitary Clinical
Subclinical cardiovascular system dysfunction in the patients with Cushing’s disease.
Klaus Witte
Tue 23 15:00
S27.1
Symposium 27: Vitamin D beyond bone
Heart & vessels
Bruce Wolffenbuttel
Mon 22 12:15
OC9.1
Oral Communications 9 - Thyroid Disease 2
Thyroid function and metabolic syndrome. Results from the population-based LifeLines Cohort Study.
Gulsah Yalin
Tue 23 11:45
OC12.1
Oral Communications 12 - Pituitary Clinical
T2-Weighted Signal Intensity of Functional Pituitary Adenomas: Correlation With Clinicopathological Findings And Response To Treatment
Christine Yedinak
Sun 21 12:15
N2.1
Nurses session: Nurses professional development and networking session
Obstructive sleep Apnea and Comorbidities in patients with Pituitary Adenomas
Maryam Zarkesh
Mon 22 12:27
OC5.2
Oral Communications 5 - Cardiovascular Endocrinology
Association of PPAR gamma gene expression with dietary intake of fat and oil among non-diabetic subjects
Ayse Zengin
Sun 21 10:30
Symposium 5: EYES session
Introduction to Eyes
Sun 21 12:15
OC1.1
Oral Communications 1 - Adrenal (Basic & Clinical)
High resolution tissue mass spectrometry imaging – a new tool for identification of prognostic markers in adrenocortical carcinoma
Sun 21 12:27
OC1.2
Oral Communications 1 - Adrenal (Basic & Clinical)
EZH2 : a master regulator of adrenal cortex homeostasis and zonation
Sun 21 12:39
OC1.3
Oral Communications 1 - Adrenal (Basic & Clinical)
Steroid Metabolomics for Accurate and Rapid Diagnosis of Inborn Steroidogenic Disorders
Sun 21 12:51
OC1.4
Oral Communications 1 - Adrenal (Basic & Clinical)
The Epidemiology of Pheochromocytoma – Increasing Incidence and Changing Clinical Presentation. A population-based retrospective study 1977-2015.
Sun 21 13:03
OC1.5
Oral Communications 1 - Adrenal (Basic & Clinical)
Diagnostic accuracy of three confirmatory tests for primary aldosteronism: a prospective study and systematic review
Sun 21 12:15
OC2.1
Oral Communications 2 - Diabetes Prediction and Complications
microRNA expression profile in plasma from patients with type 1 diabetes: a case-control study and bioinformatics analysis
Sun 21 12:27
OC2.2
Oral Communications 2 - Diabetes Prediction and Complications
Effectiveness Of Complex Therapy In Patients With Comorbidity Of Type 2 Diabetes And Essential Hypertension Depending On Genetic Polymorphism PPARγ2
Sun 21 12:39
OC2.3
Oral Communications 2 - Diabetes Prediction and Complications
GLP-1 based multi-agonists-induced signaling includes profound TRP channel involvement in insulin secretion
Sun 21 12:51
OC2.4
Oral Communications 2 - Diabetes Prediction and Complications
Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial
Sun 21 13:03
OC2.5
Oral Communications 2 - Diabetes Prediction and Complications
Urinary peptidomics for the detection of diabetic kidney disease
Sun 21 12:15
OC3.1
Oral Communications 3 - Receptors & Signalling
Epigenetic regulation of aldosterone synthase gene, CYP11B2 by potassium
Sun 21 12:27
OC3.2
Oral Communications 3 - Receptors & Signalling
Elucidating the role of Liver X receptors (LXRs) in the testis using lipid systems biology.
London, UK
Sun 21 12:39
OC3.3
Oral Communications 3 - Receptors & Signalling
AKR1C3-mediated adipose androgen generation drives lipotoxicity in polycystic ovary syndrome
Dublin, Ireland
Sun 21 12:51
OC3.4
Oral Communications 3 - Receptors & Signalling
Treatment with thyroid hormone metabolite 3,5-T2 alters cholesterol and sex steroid metabolism in mouse liver
Sun 21 13:03
OC3.5
Oral Communications 3 - Receptors & Signalling
Accurate staging of non-alcoholic fatty liver disease through analysis of the urinary steroid metabolome
Sun 21 12:15
OC4.1
Oral Communications 4 - Thyroid Disease 1
Hypothyroidism in pregnancy is associated with twin pregnancies and with adverse obstetric outcome: Analysis of 142,277 deliveries data from a single center
Sun 21 12:27
OC4.2
Oral Communications 4 - Thyroid Disease 1
Inducible thyrocyte-specific Gs alpha-deficient mice as a novel model for hypothyroidism
Sun 21 12:39
OC4.3
Oral Communications 4 - Thyroid Disease 1
A Novel Variant In The SERPINA7 Gene Causing Partial TBG Deficiency In A Woman And Two Male Siblings: Molecular and Protein Structural analysis
Sun 21 12:51
OC4.4
Oral Communications 4 - Thyroid Disease 1
The TSH receptor reaches the trans-Golgi network to induce PKA activation and trigger gene transcription
Sun 21 13:03
OC4.5
Oral Communications 4 - Thyroid Disease 1
Levothyroxine replacement therapy: once treatment is started, should it last indefinitely?
Mon 22 12:15
OC5.1
Oral Communications 5 - Cardiovascular Endocrinology
Polarized epithelial cells release exosomes loaded with miRNAs capable of interacting with HSD11B2 and MR genes
Mon 22 12:27
OC5.2
Oral Communications 5 - Cardiovascular Endocrinology
Association of PPAR gamma gene expression with dietary intake of fat and oil among non-diabetic subjects
Mon 22 12:39
OC5.3
Oral Communications 5 - Cardiovascular Endocrinology
Cardio Metabolic Assessment of Lamin A/C Mutation Carriers According To R482 or Non-R482 Mutation
Mon 22 12:51
OC5.4
Oral Communications 5 - Cardiovascular Endocrinology
Food History Characterization of Portuguese Centenarians, Nutritional Biomarkers And Cardiovascular Risk: Case Control Study
Mon 22 13:03
OC5.5
Oral Communications 5 - Cardiovascular Endocrinology
Sex Dimorphism of Renal Corticosteroid Signaling during development and long term consequence on blood pressure.
Mon 22 12:15
OC6.1
Oral Communications 6 - Diabetes Therapy and Complications
A passe-PAR2 for beta-cell regeneration and protection
Mon 22 12:27
OC6.2
Oral Communications 6 - Diabetes Therapy and Complications
Insulin-Mimetic Effects of Short-Term Rapamycin in Type 1 Diabetic Patients prior Islet Transplantation
Mon 22 12:39
OC6.3
Oral Communications 6 - Diabetes Therapy and Complications
Alterations in DNA methylation from peripheral blood cells in humans treated with metformin.
Mon 22 12:51
OC6.4
Oral Communications 6 - Diabetes Therapy and Complications
Copeptin and its association to cardiovascular dysfunction in type 2 diabetes
Mon 22 13:03
OC6.5
Oral Communications 6 - Diabetes Therapy and Complications
Activation of the Renin-Angiotensin II-Aldosterone-System Leads to Increases in Extracellular Protein Disulfide Isomerase Activity: Role in Insulin Resistance
Mon 22 12:15
OC7.1
Oral Communications 7 - Endocrine Tumours
Estrogens enhance gonadectomy-induced adrenocortical tumor progression in mice
Mon 22 12:27
OC7.2
Oral Communications 7 - Endocrine Tumours
Targeted molecular markers derived from genomic classification for Adrenocortical Cancer prognostication
Mon 22 12:39
OC7.3
Oral Communications 7 - Endocrine Tumours
High Total 68Ga-DOTATATE-Avid Tumor Volume (TV) is Associated with Low Progression-Free Survival and High Disease-Specific Mortality Rate in Patients with Neuroendocrine Tumors
Mon 22 12:51
OC7.4
Oral Communications 7 - Endocrine Tumours
A novel insight into the anticancer mechanism of metformin in Pancreatic Neuroendocrine Tumor cells
Mon 22 13:03
OC7.5
Oral Communications 7 - Endocrine Tumours
Regulation of Steroid Receptor Signalling by Tumor Suppressor INPP4B
Mon 22 12:15
OC8.1
Oral Communications 8 - Neuroendocrinology
Elucidating the molecular mechanisms underlying AIP dependent tumorigenesis.
Mon 22 12:27
OC8.2
Oral Communications 8 - Neuroendocrinology
Knocking down/out the prokineticin pathway during zebrafish development results in the GnRH neurons axons misguiding
Mon 22 12:39
OC8.3
Oral Communications 8 - Neuroendocrinology
RNA sequencing and RT-qPCR identify different gene expression profiles in fast- vs. slow-growing non-functioning pituitary adenomas
Mon 22 12:51
OC8.4
Oral Communications 8 - Neuroendocrinology
Cerebrovascular stroke incidence in GH-Treated Adults: Experience from KIMS (Pfizer International Metabolic Database)
Mon 22 13:03
OC8.5
Oral Communications 8 - Neuroendocrinology
Ephrin-B2 is required for pituitary development
Mon 22 12:15
OC9.1
Oral Communications 9 - Thyroid Disease 2
Thyroid function and metabolic syndrome. Results from the population-based LifeLines Cohort Study.
Mon 22 12:27
OC9.2
Oral Communications 9 - Thyroid Disease 2
Effect of restoration of euthyroidism in patients with hypothyroidism on cold induced thermogenesis
Mon 22 12:39
OC9.3
Oral Communications 9 - Thyroid Disease 2
How much of the genetic predisposition to Hashimoto’s thyroiditis can be explained by genes commonly associated with the disease?
Mon 22 12:51
OC9.4
Oral Communications 9 - Thyroid Disease 2
Thyroid dysfunction during the use of PD-1/PD-L1 blockade predicts its therapeutic response in the patients with advanced non-small cell lung cancer
Mon 22 13:03
OC9.5
Oral Communications 9 - Thyroid Disease 2
Selenium Supplementation In The Management Of Thyroid Autoimmunity During Pregnancy: Results Of The ‘Serena Study' A Randomized, Double-Blind, Placebo-Controlled trial.
Tue 23 11:45
OC14.1
Oral Communications 14 - Thyroid Cancer
Anti-Mullerian hormone (AMH) in pre-menopausal females after ablative radioiodine (RAI) treatment for differentiated thyroid cancer (DTC): single-center study.
Tue 23 11:57
OC14.2
Oral Communications 14 - Thyroid Cancer
Suppression of heme oxygenase-1 inhibits growth and invasion of thyroid cancer
Tue 23 12:09
OC14.3
Oral Communications 14 - Thyroid Cancer
TERT, BRAF and NRAS in the molecular profile of metastatic thyroid cancer: differences between primary and distant disease
Tue 23 12:21
OC14.4
Oral Communications 14 - Thyroid Cancer
Inverse relation between thyroid cancer incidence and threshold for thyroid surgery: a national population-based retrospective study
Tue 23 12:33
OC14.5
Oral Communications 14 - Thyroid Cancer
Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classical papillary carcinoma?
Tue 23 11:45
OC13.1
Oral Communications 13 - Reproduction & Endocrine Disruption
Abstract withdrawn
Tue 23 11:57
OC13.2
Oral Communications 13 - Reproduction & Endocrine Disruption
Thyroid peroxidase antibodies do not predict outcome in 900 women with recurrent pregnancy loss
Tue 23 12:09
OC13.3
Oral Communications 13 - Reproduction & Endocrine Disruption
Sertoli Cell Expressed Hydroxysteroid (17BETA) Dehydrogenase 1 Is Required For Male Fertility
Tue 23 12:21
OC13.4
Oral Communications 13 - Reproduction & Endocrine Disruption
Diabetes mellitus: a new cause of male infertility
Tue 23 12:33
OC13.5
Oral Communications 13 - Reproduction & Endocrine Disruption
Urinary cadmium excretion is associated with increased synthesis of cortico- and sex steroids in a family-based Swiss population study
Tue 23 11:45
OC12.1
Oral Communications 12 - Pituitary Clinical
T2-Weighted Signal Intensity of Functional Pituitary Adenomas: Correlation With Clinicopathological Findings And Response To Treatment
Tue 23 11:57
OC12.2
Oral Communications 12 - Pituitary Clinical
Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: Results from a European Society of Endocrinology (ESE) survey.
Tue 23 12:09
OC12.3
Oral Communications 12 - Pituitary Clinical
Recombinant Growth Hormone added to physical therapy in GH-deficient adults with complete (ASIA A) Spine Injury (EudraCT 2011-005377-23)
Tue 23 12:21
OC12.4
Oral Communications 12 - Pituitary Clinical
Subclinical cardiovascular system dysfunction in the patients with Cushing’s disease.
Tue 23 12:33
OC12.5
Oral Communications 12 - Pituitary Clinical
Effects of Pegvisomant And Somatostatin Receptor Ligands On Risk Of Vertebral Fractures In Patients With Acromegaly
Tue 23 11:45
OC11.1
Oral Communications 11 - Obesity
Role of Extracellular Vesicles In The Crosstalk Between Adipocytes And Pancreatic Beta-Cells
Tue 23 11:57
OC11.2
Oral Communications 11 - Obesity
Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)
Tue 23 12:09
OC11.3
Oral Communications 11 - Obesity
Interleukin-1 antagonism decreases cortisol levels in obese individuals
Tue 23 12:21
OC11.4
Oral Communications 11 - Obesity
Comparing effects of weight loss by liraglutide with intensive lifestyle modification on hepatic steatosis, inflammation and stiffness, and insulin resistance in obese Asians with non-alcoholic fatty liver disease (NAFLD)
Tue 23 12:33
OC11.5
Oral Communications 11 - Obesity
Differentiating constitutional thinness from anorexia nervosa in DSM 5 era
Tue 23 11:45
OC10.1
Oral Communications 10 - Bone & Calcium Homeostasis
Treatment of 711 patients with hypoparathyroidism: a retrospective study in 3 German Endocrine Centres.
Tue 23 11:57
OC10.2
Oral Communications 10 - Bone & Calcium Homeostasis
Evaluation of bone quality, measured by trabecular bone score (TBS) in patients with primary hyperparathyroidism (PHH) with and without surgery
Tue 23 12:09
OC10.3
Oral Communications 10 - Bone & Calcium Homeostasis
High prevalence of radiological vertebral fractures in patients with differentiated thyroid carcinoma undergoing L-thyroxine TSH-suppressive therapy
Tue 23 12:21
OC10.4
Oral Communications 10 - Bone & Calcium Homeostasis
The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment
Tue 23 12:33
OC10.5
Oral Communications 10 - Bone & Calcium Homeostasis
Gα11-Phe220Ser loss-of-function mutation causes familial hypocalciuric hypercalcemia type-2 (FHH2) by disrupting a hydrophobic cluster critical for G-protein signaling
Birmingham, UK
Sun 21 08:15
MTE1
Meet the expert 1
How to manage diabetes in the elderly?
Sun 21 08:15
MTE2
Meet the expert 2
Diagnosis and treatment of GH-deficiency: from transition to senescence
Sun 21
MTE3
Meet the expert 3
Hormone-secreting adrenal tumours in pregnancy
London, UK
Sun 21
MTE4
Meet the expert 4
Optimised treatment for congenital hypothyroidism throughout lifetime
Berlin, Germany
Sun 21
MTE5
Meet the expert 5
Modern spectrum of bone turnover markers - Are they clinically useful?
Sheffield, UK
Sun 21 08:15
Meet the nurse expert
Endocrine late effects of cancer treatment in children: providing nursing care and seamless transition
Sun 21
MTBS1
Meet the basic scientist
Unravelling the role of transient receptor potential channels in endocrine regulation and metabolism
Mon 22 08:15
MTE6
Meet the expert 6
How best to utilise technology in diabetes?
Amsterdam, The Netherlands
Mon 22 08:15
MTE7
Meet the expert 7
When and which treatment to use in Graves disease?
Mon 22
MTE8
Meet the expert 8
How best to manage neuroendocrine tumours? - towards a new algorithm
Mon 22 08:15
MTE9
Meet the expert 9
Sarcopenia- Why should we care?
Mon 22 08:15
MTBS2
Meet the basic scientist
Neuroimaging in obesity and diabetes: regulation and dysregulation of appetite and satiety
Mon 22 08:15
MTNE1
Meet the nurse expert
Providing nursing care for the adult patient with endocrine late effects of cancer treatment
Lund, Sweden
Mon 22 08:15
MTE10
Meet the Expert 10
Contraception in women with obesity, metabolic syndrome and diabetes
Tue 23
MTE11
Meet the expert 11
Drug induced osteoporosis
Tue 23 08:15
MTE12
Meet the expert 12
A modern approach for treatment PCOS
Tue 23
MTE13
Meet the expert 13
What can new insulins provide for management of diabetes?
Tue 23 08:15
MTE14
Meet the expert 14
Thyroid carcinoma: complicated cases
Tue 23 08:15
MTE15
Meet the expert 15
Gaucher's disease: interdisciplinary management
Tue 23
MTE16
Meet the expert 16
New treatment approaches in dyslipidemia
Tue 23
MTBS3
Meet the basic scientist
MicroRNAs and the regulation of glucose and lipid metabolism
Sat 20
GH1
Geoffrey Harris Lecture
Toward hormone-based precision medicines for metabolic diseases
Munich, Germany
Sat 20
EJE1
European Journal of Endocrinology Prize Lecture
Hypothalamic AMPK: a golden target against obesity?
Sat 20
P1
Plenary 1
The fantastical world of hormones
Oxford, United Kingdom
Sun 21 09:30
P2
Plenary 2
The secret life of FGF21
Sun 21 17:30
P3
Plenary 3
Update on regulation of steroidogenesis by aberrant hormone receptors
Mon 22
P4
Plenary 4
The role of brain insulin resistance for the development of prediabetic phenotypes
Mon 22 18:00
P5
Plenary 5
Browning of adipose tissue and metabolic regulation
Stockholm, Sweden
Tue 23
P6
Plenary 6
Thyroid oncology in the crossroads of precision and narrative medicine
Sun 21 10:00
Tea & Coffee
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Sun 21 13:15
Lunch and poster veiwing
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Sun 21 17:00
Tea & Coffee
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Mon 22 10:00
Tea & Coffee
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Mon 22 13:15
Lunch & poster veiwing
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Mon 22 13:30
ESE President meets new members
Restaurant (Foyer F)
Mon 22 17:00
Tea & Coffee
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Tue 23 09:30
Tea & Coffee
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Tue 23 12:45
Lunch & poster veiwing
EXHIBITION AREA - PAVILION 2 (RIO PAVILION) & GALLERY
Tue 23 16:30
Tea & Coffee
FOYER D
Sun 21 10:30
N1.1
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Diagnosis and management of hypothyroidism in patients with diabetes mellitus
Sun 21 10:50
N1.2
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Links between hypogonadism, the metabolic syndrome and type 2 diabetes
Lausanne, Switzerland
Sun 21 11:10
N1.3
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Challenges in the management of patients with Cushing’s syndrome and diabetes
Sun 21 11:30
N1.4
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
At risk of two endocrine emergencies: the patient with Type 1 diabetes and Addison’s disease
Sun 21 11:50
Nurses session: Diabetes meets endocrinology – clinical practice overlap and seamless care
Q&A with panel
Sun 21 12:15
N2.1
Nurses session: Nurses professional development and networking session
Obstructive sleep Apnea and Comorbidities in patients with Pituitary Adenomas
Sun 21 12:30
N2.2
Nurses session: Nurses professional development and networking session
Utilising the Competence Framework to develop the role of Endocrine Nurses in Adrenal Insufficiency
Sun 21 12:45
N2.3
Nurses session: Nurses professional development and networking session
Introducing the E-learning module in Adrenal Insufficiency for endocrine nurses in The Netherlands
't Harde, The Netherlands
Sun 21 12:55
N2.4
Nurses session: Nurses professional development and networking session
Developing a european position statement for endocrine nurses providing care for patients with adrenal insufficiency
London, UK
Sun 21 13:15
Nurses session: Nurses professional development and networking session
Presentation of the Best Nursing Poster award for ECE2017, poster displays and networking session with lunch and refreshments
Mon 22 15:30
N3.1
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Prevalance and treatment of vitamin D deficiency in children
Mon 22 16:00
N3.2
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Sexual hormones and bone, a close link throughout lifespan
Mon 22 16:30
N3.3
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Prevention and management of post - menopausal osteoporosis
Mon 22 17:00
Nurses session: Update on diet and lifestyle throughout lifespan to improve health
Networking session
Sat 20 12:00
Registration
FOYER A
Sat 20 12:00
Pre -Congress Courses & Meetings: Please click link for full programmes and registration details
Sat 20 17:30
ECE 2017 Opening Ceremony
AUDITORIUM I
Sat 20 20:00
Welcome reception
FOYER C & FOYER D
Sun 21 08:00
Registration
FOYER A
Sun 21 09:15
Presidential Address
A J. van der Lely (The Netherlands)
AUDITORIUM I
Sun 21
ENDO-ERN session
Introduction and view from the ESE clinical committee
France
Sun 21
ENDO-ERN session
Endo-ERN: introduction to a unique network
Sun 21
ENDO-ERN session
Opportunities, priorities, & dissemination of expertise
Copenhagen, Denmark
Sun 21
ENDO-ERN session
The patient’s view
Sun 21
ENDO-ERN session
Concluding remarks and Q&A
Sun 21 14:15
NSA1
New Scientific Approach 1
Identifying molecular signatures for cancer patient stratification via metabolomics and integrative bioinformatics
Sun 21 14:15
NSA2
New Scientific Approach 2
Exosome profiling: potential in cancer diagnosis and stratification
Mon 22 08:00
Registration
FOYER A
Mon 22
EHM1
European Hormone Medal Lecture
Endocrine disruptors: Is it all Greek to us?
Mon 22
D3.1
Debate 3: Drug holiday in osteoporosis
For
Aarhus, Denmark
Mon 22
D3.2
Debate 3: Drug holiday in osteoporosis
Against
Mon 22
D4.1
Debate 4: Is cardiovascular risk increased in women with PCOS?
For
Mon 22
D4.2
Debate 4: Is cardiovascular risk increased in women with PCOS?
Against
Mon 22 14:15
NSA3
New scientific approach 3
Genomic approaches on epigenetics
Mon 22 14:15
NSA4
New scientific approach 4
What is the CRISPR CAS9 technology?
Lyon, France
Mon 22
CET1
Clinical Endocrinology Trust Lecture
New perspectives on the definition and management of the polycystic ovary syndrome
Tue 23 08:00
Registration
FOYER A
Tue 23 09:00
IPSEN1
IPSEN Fondation Lecture
Endocrine Regulations Prize lecture : Redefining neuroendocrinology: stress, sex and cognitive and emotional regulation
Tue 23
D5.1
Debate 5: Should we still ablate all patients undergoing total thyroidectomy for thyroid cancer?
For
Tue 23
D5.2
Debate 5: Should we still ablate all patients undergoing total thyroidectomy for thyroid cancer?
Against
Geneva, Switzerland
Tue 23
D6.1
Debate 6: Is it time for initial combination in type 2 diabetes?
For
Tue 23
D6.2
Debate 6: Is it time for initial combination in type 2 diabetes?
Against
Tue 23 13:00
ESE Annual General Meeting
Members only
AUDITORIUM III & IV
Tue 23 13:45
NSA5.1
New scientific approach 5
New strategies to crystallize endocrine disease related-GPCRs
Tue 23 14:05
NSA5.2
New scientific approach 5
Small molecule agonists and antagonists as potential new therapeutics targeting the TSH receptor
Tue 23 13:45
NSA6
New scientific approach 6
Mitochondrial epigenetics in obesity and its co-diseases
Tue 23 17:00
ESE Young Investigator awards ceremony
AUDITORIUM I
Tue 23 17:45
Closing Ceremony
AUDITORIUM I
Sun 21 10:30
S1.1
Symposium 1: Clinical updates in Hypoparathyrodism
Congenital hypoparathyroidism
Paris, France
Sun 21 11:00
S1.2
Symposium 1: Clinical updates in Hypoparathyrodism
Acquired hypoparathyroidism

Unknown speaker

Oxford, UK
Sun 21 11:30
S1.3
Symposium 1: Clinical updates in Hypoparathyrodism
Therapeutic approaches
Sun 21 10:30
S2.1
Symposium 2: Evolving diagnostics in adrenal and neuroendocrine tumours
Role of genetic and biomarker tests for diagnosis of neuroendocrine tumours (NETs)
Oxford, United Kingdom
Sun 21 11:00
S2.2
Symposium 2: Evolving diagnostics in adrenal and neuroendocrine tumours
Current status in morphological imaging in adrenal and gastrointestinal neuroendocrine tumours
Sun 21 11:30
S2.3
Symposium 2: Evolving diagnostics in adrenal and neuroendocrine tumours
Current status in functional imaging
Sun 21 10:30
S3.1
Symposium 3: From the pituitary to the periphery
Implication of the prolactin receptor in humans
Sun 21 11:00
S3.2
Symposium 3: From the pituitary to the periphery
GHR : are there benefits of endocrine defects?
Ohio, USA
Sun 21 11:30
S3.3
Symposium 3: From the pituitary to the periphery
Somatostatin receptors: news in the pituitary, lessons for the periphery
Sun 21 10:30
S4.1
Symposium 4: 2nd Joint Global Symposium on Obesity - the many dimensions of the childhood globesity problem
Efficacy & Effectiveness of Physical Activity & Nutrition Interventions in Childhood Obesity Treatment
Sun 21 11:00
S4.2
Symposium 4: 2nd Joint Global Symposium on Obesity - the many dimensions of the childhood globesity problem
The Hunger Genes: Pathways to Obesity
Cambridge, UK
Sun 21 11:30
S4.3
Symposium 4: 2nd Joint Global Symposium on Obesity - the many dimensions of the childhood globesity problem
Policy Response to Childhood Obesity
Sun 21 10:30
Symposium 5: EYES session
Introduction to Eyes
Sun 21 10:40
S5.1
Symposium 5: EYES session
Effects of maternal thyroid function on infant neurodevelopment
Netherlands, Netherlands
Sun 21 11:00
S5.2
Symposium 5: EYES session
Vitamin D and rickets in African children
Cambridge, UK
Sun 21 11:20
S5.3
Symposium 5: EYES session
Carbohydrate metabolism in patients with Cushing disease: a glance at the incretin system
Sun 21 11:40
S5.4
Symposium 5: EYES session
Endocrine Connections - the place to publish for the early career endocrinologist
Sun 21 11:50
Symposium 5: EYES session
Eyes activities and invitation to Eyes annual meeting
Sun 21 10:30
Guidelines session 1: Management of Turner Syndrome
Introduction
Sun 21 10:40
Guidelines session 1: Management of Turner Syndrome
Growth and puberty induction
Rotterdam, The Netherlands
Sun 21 11:10
Guidelines session 1: Management of Turner Syndrome
Adult aspects
Sun 21 11:40
Guidelines session 1: Management of Turner Syndrome
The heart in Turner syndrome
Cincinnati, USA
Sun 21 15:30
S6.1
Symposium 6: Treatment of hypothyroidism: what have we learned?
What is the clinical relevance of deiodinase polymorphisms?
Chicago, USA
Sun 21 16:00
S6.2
Symposium 6: Treatment of hypothyroidism: what have we learned?
T4/T3 combination therapy: is there a true effect?
Amsterdam, The Netherlands
Sun 21 16:30
S6.3
Symposium 6: Treatment of hypothyroidism: what have we learned?
Rebuilding your own thyroid from stem cells; the future therapy of hypothyroidism?
Boston, USA
Sun 21 15:30
S7.1
Symposium 7: Crosstalk between bone & other organ(ism)s
Immune system
Sun 21 16:00
S7.2
Symposium 7: Crosstalk between bone & other organ(ism)s
Regulation of adaptation to exercise by Osteocalcin
Sun 21 16:30
S7.3
Symposium 7: Crosstalk between bone & other organ(ism)s
Microbiome
Sun 21 15:30
S8.1
Symposium 8: Predictors of therapeutic response in functioning pituitary tumours
Molecular profiling
Sun 21 16:00
S8.2
Symposium 8: Predictors of therapeutic response in functioning pituitary tumours
Imaging
Sun 21 16:30
S8.3
Symposium 8: Predictors of therapeutic response in functioning pituitary tumours
Clinical application and practice
Sun 21 15:30
S9.1
Symposium 9: Novel type 2 diabetes treatment: beyond glycaemic control
Experimental models
Sun 21 16:00
S9.2
Symposium 9: Novel type 2 diabetes treatment: beyond glycaemic control
Clinical studies on GLP1 - cardiovascular outcomes
Sun 21 16:30
S9.3
Symposium 9: Novel type 2 diabetes treatment: beyond glycaemic control
SGLT2 inhibition: long term protective effects
Sun 21 15:30
S10.1
Symposium 10: The challenges of Male Fertility
Manipulating testicular androgen production to promote lifelong male health
New South Wales, Australia
Sun 21 16:00
S10.2
Symposium 10: The challenges of Male Fertility
Fertility preservation in pre-pubertal and young males
Sun 21 16:30
S10.3
Symposium 10: The challenges of Male Fertility
Pubertal induction and hormone replacement in young males
Lausanne, Switzerland
Mon 22 10:30
S11.1
Symposium 11: New Roles for Nuclear Receptors
Identification of nuclear receptors network in male fertility
Clermont-Ferrand, France
Mon 22 11:00
S11.2
Symposium 11: New Roles for Nuclear Receptors
Crosstalk between estrogen signalling and DNA damage repair
London, UK
Mon 22 11:30
S11.3
Symposium 11: New Roles for Nuclear Receptors
The role of androgens in bone
KU Leuven University, Leuven
Mon 22 10:30
S12.1
Symposium 12: New developments in Graves' orbitopathy
The orbital fibroblast: a key player and target for therapy in graves' orbitopathy
Mon 22 11:00
S12.2
Symposium 12: New developments in Graves' orbitopathy
Management of Graves orbitopathy
Mon 22 11:30
S12.3
Symposium 12: New developments in Graves' orbitopathy
How to predict progression in Graves' orbitopathy
United Kingdom
Mon 22 10:30
S13.1
Symposium 13: Challenging pituitary diseases
Hypophysitis
Birmingham, UK
Mon 22 11:00
S13.2
Symposium 13: Challenging pituitary diseases
Empty sella
Mon 22 11:30
S13.3
Symposium 13: Challenging pituitary diseases
Sellar masses
Erlangen, Germany
Mon 22 10:30
S14.1
Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
Rare Cushing's
Mon 22 11:00
S14.3
Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
Rare hypoglycemia
Mon 22 11:00
S14.2
Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
Rare acromegaly
Mon 22 10:30
S15.1
Symposium 15: Metabolic surgery: mechanisms to clinical results
The upper gut anti-incretin theory
Mon 22 11:00
S15.2
Symposium 15: Metabolic surgery: mechanisms to clinical results
The role of bile in metabolic surgery
Mon 22 11:30
S15.3
Symposium 15: Metabolic surgery: mechanisms to clinical results
Long term effects of metabolic surgery
Mon 22 15:30
S16.1
Symposium 16: Late-breaking: the PCSK9 revolution
Beyond LDL lowering: the pleiotropic roles of PCSK9
Mon 22 16:00
S16.2
Symposium 16: Late-breaking: the PCSK9 revolution
New strategies for inhibiting PCSK9
Mon 22 16:30
S16.3
Symposium 16: Late-breaking: the PCSK9 revolution
PCSK9 inhibition in clinical practice: present and future
Mon 22 15:30
S17.1
Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
Clinical consequences of the recent genomics findings in thyroid cancer
Ann Arbor, USA
Mon 22 16:00
S17.2
Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
Clinical implications of SDH mutations
Paris, France
Mon 22 16:30
S17.3
Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
Will genomics help to finally classify NETs?
Mon 22 15:30
S18.1
Symposium 18: Hyperandrogenism: challenges in clinical management
Hyperandrogenic states: pitfalls in diagnostic approach
Mon 22 16:00
S18.2
Symposium 18: Hyperandrogenism: challenges in clinical management
Metabolic perspectives for the non-classical CAH
Mon 22 16:30
S18.3
Symposium 18: Hyperandrogenism: challenges in clinical management
Hyperandrogenism and cardiometabolic risk
Mon 22 15:30
S19.1
Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
Treatment and follow-up of microcarcinomas
Mon 22 16:00
S19.2
Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
When and how should we perform extensive surgery?
Mon 22 16:30
S19.3
Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
Dynamic risk stratification in low-risk vs high-risk patients
Mon 22 15:30
S20.1
Symposium 20: Beta cell replacement and plasticity
Reprogramming and differentiation of skin fibroblasts into beta cells for the cure of diabetes
Mon 22 16:00
S20.2
Symposium 20: Beta cell replacement and plasticity
New Strategies for beta cell replacement
Mon 22 16:30
S20.3
Symposium 20: Beta cell replacement and plasticity
Induction of pancreatic beta-like cell neogenesis
Nice, France
Mon 22
Guidelines sessions 2
Mon 22
Guidelines sessions 2
Mon 22
Guidelines sessions 2
Mon 22
Guidelines sessions 2
Mon 22
Guidelines sessions 2
Mon 22
Guidelines sessions 2
Tue 23 10:00
S21.1
Symposium 21: Environmental influences on endocrine systems
Lifestyle and environmental factors in metabolic diseases
Tue 23 10:30
S21.2
Symposium 21: Environmental influences on endocrine systems
Evidence on reproductive disorders through endocrine disruption in-utero
Tue 23 11:00
S21.3
Symposium 21: Environmental influences on endocrine systems
EUthyroid: Towards a euthyroid Europe
Tue 23 10:00
S22.1
Symposium 22: Rare bone diseases
Approach for clinicians
Tue 23 10:30
S22.2
Symposium 22: Rare bone diseases
Osteogenesis imperfecta & Ehlers-Danlos Syndrome
Tue 23 11:00
S22.3
Symposium 22: Rare bone diseases
Fibrous dysplasia
Tue 23 10:00
S23.1
Symposium 23: Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis
Prolactin regulation of prostate stem cells : potential implications in prostate cancer
Tue 23 10:30
S23.2
Symposium 23: Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis
Does GH enable neoplastic growth?
Los Angeles CA , USA
Tue 23 11:00
S23.3
Symposium 23: Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis
Is reducing insulin-resistance relevant to prevent cancer?
Tue 23 10:00
S24.1
Symposium 24: Obesity: Pharmacological solutions
MSH analogs
Berlin, Germany
Tue 23 10:30
S24.2
Symposium 24: Obesity: Pharmacological solutions
The future drugs to come
Tue 23 11:00
S24.3
Symposium 24: Obesity: Pharmacological solutions
Solutions update for medically complicated obesity
Glasgow, United Kingdom
Tue 23 10:00
S25.1
Symposium 25: HPA axis regulation during a woman's life: impact on metabolic outcomes
Molecular basis of the HPA axis regulation in woman during stress and pregnancy
Tue 23 10:30
S25.2
Symposium 25: HPA axis regulation during a woman's life: impact on metabolic outcomes
HPA axis, insulin resistance and adipocytokines in the fetal-maternal unit
Tue 23 11:00
S25.3
Symposium 25: HPA axis regulation during a woman's life: impact on metabolic outcomes
11β-hydroxysteroid dehydrogenase activity, androgen excess, and metabolic outcomes in woman
Oxford, UK
Tue 23 15:00
S26.1
Symposium 26: Tissue specific defects in thyroid hormone action
Mouse models to study tissue specific hypothyroidism
Essen, Germany
Tue 23 15:30
S26.2
Symposium 26: Tissue specific defects in thyroid hormone action
Syndromes of decreased sensitivity to TH
Cambridge, United Kingdom
Tue 23 16:00
S26.3
Symposium 26: Tissue specific defects in thyroid hormone action
Restoring TH action in patients with transporter defects: the Triac Trial
Tue 23 15:00
S27.1
Symposium 27: Vitamin D beyond bone
Heart & vessels
Tue 23 15:30
S27.2
Symposium 27: Vitamin D beyond bone
Fertility
Tue 23 16:00
S27.3
Symposium 27: Vitamin D beyond bone
Muscles
Tue 23 15:00
S28.1
Symposium 28: Sleep, love and reproduction
Candidate mechanisms underlying the association between poor sleep and obesity
Tue 23 15:30
S28.2
Symposium 28: Sleep, love and reproduction
Oxytocin: from biology to love
Tue 23 16:00
S28.3
Symposium 28: Sleep, love and reproduction
Kisspeptin & Neurokinin B
London, UK
Tue 23 15:00
S29.1
Symposium 29: Novel predictors of diabetes
Type 1 Diabetes
Tue 23 15:30
S29.2
Symposium 29: Novel predictors of diabetes
Clinical and genetic indicators
Tue 23 16:00
S29.3
Symposium 29: Novel predictors of diabetes
NAFLD, diabetes and CVD
Tue 23 15:00
S30.1
Symposium 30: Moving away from old-fashioned steroidogenesis: what are the clinical implications?
Clinical relevance of alternative synthesis of androgens
Tue 23 15:30
S30.2
Symposium 30: Moving away from old-fashioned steroidogenesis: what are the clinical implications?
Clinical relevance of steroid precursors in adrenocortical tumors
Birmingham, United Kingdom
Tue 23 16:00
S30.3
Symposium 30: Moving away from old-fashioned steroidogenesis: what are the clinical implications?
Glucocorticoid production in primary aldosteronism – from mechanisms to clinical implications
Zürich, Switzerland
Mon 22 12:15
European Union of Medical Specialists (UEMS), Section of Endocrinology
Introduction
Mon 22 12:20
European Union of Medical Specialists (UEMS), Section of Endocrinology
Endocrine Training and Service around Europe
London, UK
Mon 22 12:50
European Union of Medical Specialists (UEMS), Section of Endocrinology
Exchange in Endocrinology Expertise (3E) Programme
Rotterdam, The Netherlands

0 result(s) found.